Highlights

  • Microba Life Sciences (ASX:MAP) reported FY26 revenue of AUD 14.76 million, down 5.8%.
  • Core testing volumes increased 78% to 22,418 tests, while core testing revenue rose 92%.
  • The company recorded a statutory net loss of AUD 20.72 million and held AUD 7.95 million in cash at year-end.
  • Management outlined an October 2026 GI Navigator launch and a 2027 group cash-flow break-even objective.

Microba Life Sciences Limited (ASX:MAP), an Australian microbiome diagnostics and therapeutics business, entered FY27 after reshaping its product range around clinical testing and own-brand supplements. At the time of writing this article on 19 October 2026, its shares were quoted at AUD 0.044, up 7.32% during today’s trading session. The company’s FY26 annual report provides a view of how increasing test volumes, the withdrawal of older products and continuing expenditure affected revenue, losses and cash resources. Its next commercial focus includes the GI Navigator testing product.

Company Business

Brisbane-based Microba uses microbiome measurement, laboratory testing and data analysis to provide information about the human gut microbiome. Its diagnostic products include Microbiome Explorer, offered to healthcare practitioners, and MetaPanel, developed for clinical applications in gastroenterology. The business also supplies Invivo-branded health products and supplements through its United Kingdom operations.

Australia and the United Kingdom are its principal active clinical testing markets. The company also maintains distribution arrangements in other regions, including the United States and parts of Europe. Its therapeutics portfolio includes intellectual property connected with live biotherapeutic products, although further internal therapeutics research and development investment has been paused as management pursues partnering arrangements.

Recent Development

The FY26 annual report, released in August 2026, documented the completion of Microba’s planned withdrawal from discontinued legacy testing lines. Continuing product revenue increased 53% to AUD 12.7 million, whereas discontinued product revenue fell 72% to AUD 2.1 million. The shift reduced reported group revenue during the transition but increased the proportion attributable to core testing.

Microba sold 22,418 core tests in FY26, compared with 12,629 in FY25. It reported 43 enterprise-clinic accounts signed in Australia from November 2025 to June 2026, which had collectively sold more than 5,600 tests. In the June quarter, Microbiome Explorer volumes reached 5,311 tests in Australia and 825 in the United Kingdom.

The annual report identified October 2026 as the planned launch period for GI Navigator, a product using the company’s Clinical Logic Engine to support gastrointestinal testing workflows. An early-access program had generated 35 sales by the time of that report. A company product update also described the September rollout of Microbiome Explorer 3.0, including revised healthy reference ranges and reporting features.

Financial Performance and Sector Context

Revenue from ordinary activities for the year ended 30 June 2026 was AUD 14.76 million, compared with AUD 15.67 million in FY25. Core testing revenue grew 92% to approximately AUD 8.6 million, reflecting changes within the product mix. Gross profit was AUD 7.03 million, with a gross margin of 47.6%, compared with 47.5% a year earlier.

The statutory net loss widened to AUD 20.72 million from AUD 14.94 million. Microba separately reported an underlying loss of AUD 18.83 million, an 11% improvement, after adjusting for identified non-cash and non-recurring items. That underlying measure is not an IFRS result. Total expenses declined 7% to AUD 29.92 million, including reductions in staffing and consulting costs.

Net operating cash outflow was AUD 12.37 million, versus AUD 12.01 million the previous year. Cash and equivalents stood at AUD 7.95 million on 30 June 2026, compared with AUD 11.7 million a year earlier. The company raised gross equity proceeds of AUD 13.0 million during FY26. As clinical microbiome testing develops, its commercial performance depends on practitioner adoption, repeat test orders and converting kits sold into completed tests and recognised revenue.

Risks to Consider

Losses and cash consumption remain central financial considerations. The annual report identified a material going-concern uncertainty if management’s funding, cost-reduction and commercial plans do not progress as assumed. Volume growth also fell short of the previous target of more than 24,000 core tests in FY26, and regional EBITDA break-even was not reached by year-end. Other risks include the timing of clinician adoption, product rollout execution, payment collection and clinical or regulatory requirements for testing services.

What to Watch Next

Developments to monitor include confirmation of the GI Navigator commercial launch, subsequent testing volumes in Australia and the United Kingdom, enterprise-clinic ordering patterns and conversion of deferred revenue into recognised sales. Management is targeting approximately AUD 7 million in annualised cost reductions once its streamlining program is fully implemented, and whole-company cash-flow break-even on a run-rate basis during calendar 2027. Both remain objectives rather than achieved outcomes.

Investors may also monitor the status of preliminary, non-binding merger discussions with Genetic Signatures Limited, disclosed in August 2026. The annual report stated that no binding agreement or decision to proceed had been made.

Key Insights

Microba’s FY26 figures show higher core testing activity alongside lower total revenue, reflecting the removal of legacy products. Expense reductions improved its adjusted loss measure, but the statutory loss increased and operating cash flow remained negative. Commercial adoption, cost reductions, liquidity and the progress of new diagnostics products will be relevant in subsequent reporting periods.